These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35101900)

  • 1. Don't worry about the drug industry's profits when considering a waiver on covid-19 intellectual property rights.
    Hawksbee L; McKee M; King L
    BMJ; 2022 Jan; 376():e067367. PubMed ID: 35101900
    [No Abstract]   [Full Text] [Related]  

  • 2. Don't worry about the drug industry's profits when considering a waiver on covid-19 intellectual property rights.
    BMJ; 2022 Feb; 376():o482. PubMed ID: 35197260
    [No Abstract]   [Full Text] [Related]  

  • 3. Profiteering from vaccine inequity: a crime against humanity?
    Hassan F; Yamey G; Abbasi K
    BMJ; 2021 Aug; 374():n2027. PubMed ID: 34400410
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessment of the proposed intellectual property waiver as a mechanism to address the COVID-19 vaccine scarcity problem.
    Barnes-Weise J; Santos Rutschman A; Adler R
    J Epidemiol Community Health; 2022 Apr; 76(4):317-318. PubMed ID: 35140119
    [No Abstract]   [Full Text] [Related]  

  • 5. Profits First, Health Second: The Pharmaceutical Industry and the Global South Comment on "More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap".
    Lexchin J
    Int J Health Policy Manag; 2024; 13():8471. PubMed ID: 39099498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patent waiver on COVID vaccines is right and fair.
    Nature; 2021 May; 593(7860):478. PubMed ID: 34035532
    [No Abstract]   [Full Text] [Related]  

  • 7. It's time to consider a patent reprieve for COVID vaccines.
    Nature; 2021 Apr; 592(7852):7. PubMed ID: 33785920
    [No Abstract]   [Full Text] [Related]  

  • 8. New WTO leader faces COVID-19 challenges.
    Zarocostas J
    Lancet; 2021 Feb; 397(10276):782. PubMed ID: 33640051
    [No Abstract]   [Full Text] [Related]  

  • 9. Is there light at the end of the Covid-19 tunnel?
    Mortimer PP
    Rev Med Virol; 2021 May; 31(3):e2173. PubMed ID: 33002254
    [No Abstract]   [Full Text] [Related]  

  • 10. Pool patents to get COVID vaccines and drugs to all.
    Billette de Villemeur E; Dequiedt V; Versaevel B
    Nature; 2021 Mar; 591(7851):529. PubMed ID: 33742180
    [No Abstract]   [Full Text] [Related]  

  • 11. Incentivising wealthy nations to participate in the COVID-19 Vaccine Global Access Facility (COVAX): a game theory perspective.
    McAdams D; McDade KK; Ogbuoji O; Johnson M; Dixit S; Yamey G
    BMJ Glob Health; 2020 Nov; 5(11):. PubMed ID: 33257418
    [No Abstract]   [Full Text] [Related]  

  • 12. The costs of coronavirus vaccines and their pricing.
    Light DW; Lexchin J
    J R Soc Med; 2021 Nov; 114(11):502-504. PubMed ID: 34732097
    [No Abstract]   [Full Text] [Related]  

  • 13. Just allocation of COVID-19 vaccines.
    Herlitz A; Lederman Z; Miller J; Fleurbaey M; Venkatapuram S; Atuire C; Eckenwiler L; Hassoun N
    BMJ Glob Health; 2021 Feb; 6(2):. PubMed ID: 33589419
    [No Abstract]   [Full Text] [Related]  

  • 14. Temporary waiver of intellectual property on Covid-19 vaccines: toward the creation of a better, post-pandemic society.
    Del Castillo FA
    J Public Health (Oxf); 2021 Sep; 43(3):e559-e560. PubMed ID: 34056662
    [No Abstract]   [Full Text] [Related]  

  • 15. Ensuring fair distribution of COVID-19 vaccines: is an intellectual waiver the answer?
    Burki TK
    Lancet Respir Med; 2021 Jul; 9(7):e64. PubMed ID: 34029536
    [No Abstract]   [Full Text] [Related]  

  • 16. Intellectual property waiver for covid-19 vaccines will advance global health equity.
    Erfani P; Binagwaho A; Jalloh MJ; Yunus M; Farmer P; Kerry V
    BMJ; 2021 Aug; 374():n1837. PubMed ID: 34344728
    [No Abstract]   [Full Text] [Related]  

  • 17. COVID-19 vaccines a global public good? Moving past the rhetoric and making work of sharing intellectual property rights, know-how and technology.
    Meijer M; Verschuuren M; Weggen E
    Eur J Public Health; 2021 Oct; 31(5):925-926. PubMed ID: 34473255
    [No Abstract]   [Full Text] [Related]  

  • 18. What scientists do and don't know about the Oxford-AstraZeneca COVID vaccine.
    Mallapaty S; Callaway E
    Nature; 2021 Apr; 592(7852):15-17. PubMed ID: 33762708
    [No Abstract]   [Full Text] [Related]  

  • 19. Inequitable COVID-19 vaccine distribution and the intellectual property rights prolong the pandemic.
    Altindis E
    Expert Rev Vaccines; 2022 Apr; 21(4):427-430. PubMed ID: 34878957
    [No Abstract]   [Full Text] [Related]  

  • 20. Waiver of Intellectual Property Rights on COVID-19 vaccine roll out.
    Cabatbat KPM
    J Public Health (Oxf); 2022 Jun; 44(2):e338. PubMed ID: 34164670
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.